Brandon May

Treatment with monoclonal antibody and dual IL-4/IL-13 inhibitor dupilumab was well tolerated and associated with sustained improvement in asthma control for up to 96 weeks

Treatment with omalizumab for up to 1 year was associated with continued improvements in symptoms of chronic rhinosinusitis with nasal polyps.

Lanadelumab was effective for reducing hereditary angioedema attacks at up to 30 weeks of treatment, suggesting the monoclonal antibody is associated with sustained long-term efficacy.

Switching from non-extra fine multi-inhaler triple therapy to single-inhaler extra-fine inhaled triple therapy improved regional ventilation to the small airways in patients with COPD.

Once-daily revefenacin when administered via a jet nebulizer with formoterol was well tolerated and associated with greater lung function response compared with formoterol alone in patients with COPD.

Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.

The use of bronchial thermoplasty resulted in improvements in asthma control and reductions in the use of corticosteroid maintenance therapies in patients with asthma.

While patients with angioedema are routinely given steroids, the use of steroids in intubated patients had no effect on intensive care unit hours, intubation length, or total length of hospital stay.

Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.

Hospitalized patients with severe COVID-19 and diabetes are less likely to be discharged from the hospital and are more likely to experience in-hospital mortality compared with patients without diabetes.